My site

LONDON - Thursday, 26. January 2023

Three quarters of business leaders do not believe their peers’ ESG reporting, according to a new study, showing that a lack of industry trust and verifiable data is driving scepticism

(BUSINESS WIRE) -- Most business leaders (76%) in major industries doubt their peers’ Environmental, Social and Governance (ESG) reporting, according to a new study by Inmarsat, the world leader in global, mobile satellite communications.

The findings come from a new global, independent research report Accelerating sustainable action through IoT commissioned by the company. It explores the views of over 1,000 senior technology and ESG decision-makers across agriculture, mining, transport, utilities and oil & gas firms. The survey asked professionals about their perceptions on ESG and whether they believed data provided by ‘Internet of Things’ (IoT) solutions could help improve reporting transparency.

Respond ... Read more »

TOKYO
(BUSINESS WIRE) -- The Japan Prize Foundation announced the winners of the 2023 Japan prize at 13:00 today, 30 January 2023 (JST). Prof. Masataka Nakazawa and Mr. Kazuo Hagimoto are co-winners of the Japan Prize in the fields of Electronics, Information, and Communication, and Prof. Gero Miesenböck and Prof. Karl Deisseroth are co-winners of the Japan Prize in the field of Life Science.

For this year’s Japan Prize, Prof. Nakazawa and Mr. Hagimoto are being recognized for their distinguished contributions to global long-distance, high-capacity optical fiber network through the development of semiconductor laser pumped optical amplifier, and Prof. Miesenböck and Prof. Deisseroth are being recognized for their development of methods that use genetically addressable light-sensitive membrane proteins to unravel neural circuit function.

For the 2023 Japan Prize, the Foundation asked approximately 15,500 prominent scientists and engineers from around the w ... Read more »

INGELHEIM, Germany - Monday, 30. January 2023 AETOSWire Print 

Spesolimab EFFISAYIL™ 2 trial showed significant prevention of generalized pustular psoriasis (GPP) flares for up to 48 weeks1,2
Results build on data from the EFFISAYIL™ 1 trial, demonstrating the rapid and sustained pustular and skin clearance in flaring adult GPP patients treated with spesolimab3
GPP is a rare and unpredictable systemic skin disease that is distinct from plaque psoriasis in both its disease mechanism and severity4
(BUSINESS WIRE) -- EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2 Safety data were in line with previously conducted clinical trials with spesolimab.

“Painful GPP flares can occur suddenly, escalate quickly, and may require urgent hospit ... Read more »

(BUSINESS WIRE)--Aspen Insurance Holdings Limited (“Aspen”) is pleased to announce that Mike Duffy has been appointed to the Aspen Managing Agency Limited (“AMAL”) and Aspen Insurance UK Limited (“AIUK”) Boards as a Non-Executive Director, effective February 1, 2023.

Mike will join the AMAL and AIUK (together, “Aspen U.K.”) Boards as Senior Independent Non-Executive Director (“SID”), Chair of the Nominations Committee, and Chair of the Governance Committee, subject to regulatory approval.

Mike is a vastly experienced and highly respected leader in the Lloyd’s market with a 40-year career across underwriting and broking. He was most recently Group Chief Underwriting Officer for Canopius, where he held several Board roles across the Canopius corporate group of entities. In addition, he has held numerous leadership positions across a range of broking and insurance groups.

During his extensive care ... Read more »